A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Recruiting now · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Key facts
- Study ID
- NCT07336446
- Run by
- AstraZeneca
- People needed
- 300
- Starts
- 2026-01-27
- Expected to finish
- 2029-01-26
- Last updated by the study team
- 2026-06-23
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Research Site — Cambridge, United Kingdom (enrolling)
- Research Site — St Louis, Missouri, United States (enrolling)
- Research Site — Myrtle Beach, South Carolina, United States (enrolling)
- Research Site — Nashville, Tennessee, United States (enrolling)
- Research Site — Melbourne, Australia (enrolling)
- Research Site — Calgary, Alberta, Canada (enrolling)
- Research Site — Kashiwa, Japan (enrolling)
- Research Site — Barcelona, Spain (enrolling)
- Research Site — Duarte, California, United States (enrolling)
- Research Site — Amsterdam, Netherlands
- Research Site — San Francisco, California, United States
- Research Site — Tampa, Florida, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Vancouver, British Columbia, Canada
- Research Site — Chengdu, China
- Research Site — Chūōku, Japan
- Research Site — Salt Lake City, Utah, United States
- Research Site — Rotterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.